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A B S T R A C T
Purpose
CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers
a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells.
Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival
versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients
with newly diagnosed secondary acute myeloid leukemia (sAML).
Patients and Methods
In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed
high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation
therapy with a similar regimen. The primary end point was overall survival.
Results
CPX-351 signiﬁcantly improvedmedian overall survival versus 7+3 (9.56 v 5.95months; hazard ratio,
0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also signiﬁcantly higher
with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomeswere observed
across age-groups and AML subtypes. The incidences of nonhematologic adverse events were
comparable between arms, despite a longer treatment phase and prolonged time to neutrophil
and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9%
and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through
day 60.
Conclusion
CPX-351 treatment is associated with signiﬁcantly longer survival compared with conventional 7+3
in older adults with newly diagnosed sAML. The safety proﬁle of CPX-351 was similar to that of
conventional 7+3 therapy.
J Clin Oncol 36:2684-2692. © 2018 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
INTRODUCTION
Acute myeloid leukemia (AML) is a heteroge-
neous disease characterized by the expansion of
malignant myeloid precursors in the blood and
bone marrow. Although most cases arise de novo,
AML can evolve from an antecedent hematologic
disorder or as a late complication of chemo-
therapy or ionizing radiation.1 Secondary AML
(sAML) accounts for approximately one quarter
of all AMLs and occurs more frequently with
advancing age.2 sAML also is associated with bi-
ologic features that contribute to poor outcomes
independent of older age, including adverse/
complex cytogenetics and multidrug resistance
phenotype.2-6
For. 40 years, the 7+3 regimens (ie, cytarabine
infused continuously for 7 days with three once-daily
injections of an anthracycline) have been a standard
for AML induction therapy.7,8 In older adults and
patients with sAML, 7+3 induction is associated with
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lower remission rates, increased early mortality, and higher relapse
rates than in younger adults and older patients with de novo
AML.9,10 Attempts to improve 7+3 with the addition of other drugs
or intensiﬁcation of postremission therapy largely have failed to
improve outcomes,11-13 although two agents14,15 were recently
approved by the US Food and Drug Administration as additions to
standard induction in speciﬁc settings.
CPX-351 (VYXEOS; Jazz Pharmaceuticals, Palo Alto, CA) is
a dual-drug liposomal encapsulation of cytarabine and dauno-
rubicin at a ﬁxed 5:1 synergistic molar ratio.16-19 In animal models,
CPX-351 demonstrated superior antileukemia activity versus free
drugs when administered at the same drug ratios.16,19 In a ran-
domized phase II study of patients age 60 to 75 years with newly
diagnosed AML, higher remission rates were observed with CPX-
351 than with 7+3 in the overall study population, with improved
overall survival (OS) and event-free survival (EFS) in the subgroup
of patients with sAML.20 On the basis of these results, we con-
ducted a randomized phase III study to compare the efﬁcacy and
safety of CPX-351 to conventional 7+3, which recently led to the
US Food and Drug Administration approval of daunorubicin:
cytarabine 44:100 mg/m2 liposome (CPX-351) for the treatment of
adults with newly diagnosed therapy-related AML or AML with
myelodysplasia-related changes.
PATIENTS AND METHODS
Study Design
This phase III, open-label study randomly assigned patients to receive
CPX-351 or conventional cytarabine and daunorubicin (7+3 cohort).
Patients were enrolled between December 2012 and November 2014 across
39 centers in the United States and Canada.
Patients were randomly assigned using a dynamic balancing ran-
domization algorithm21 in a 1:1 ratio to receive CPX-351 or 7+3 as in-
duction and consolidation chemotherapy. They were stratiﬁed by age (60
to 69 v 70 to 75 years) and AML type (ﬁve subtypes: therapy-related AML,
AMLwith a history of myelodysplastic syndrome [MDS] with and without
prior hypomethylating agents, AML with a history of chronic myelo-
monocytic leukemia [CMML], de novo AML with MDS-related cytoge-
netic abnormalities).
Patients could receive up to two cycles of induction chemotherapy to
achieve complete remission (CR) or CR with incomplete neutrophil or
platelet recovery (CRi)22 followed by up to two cycles of consolidation
therapy. The initial CPX-351 induction course consisted of 100 units/m2
(100 mg/m2 cytarabine and 44 mg/m2 daunorubicin) administered as a
90-minute infusion on days 1, 3, and 5. A second induction course (same
dose) was administered on days 1 and 3 for patients who did not achieve
hypoplastic marrow on a day 14 bone marrow assessment. For patients in
CR/CRi after induction, postremission therapy consisted of up to two
cycles of 65 units/m2 CPX-351 (65 mg/m2 cytarabine and 29 mg/m2
daunorubicin) on days 1 and 3. The 7+3 control cohort consisted of an
initial induction course of cytarabine 100 mg/m2/d administered by 7-day
continuous infusion with daunorubicin 60 mg/m2 on days 1 to 3. The
second induction course and postremission consolidation courses con-
sisted of cytarabine 100 mg/m2/d by 5-day continuous infusion with
daunorubicin 60 mg/m2 on days 1 and 2. Allogeneic hematopoietic cell
transplantation (HCT) was performed at the discretion of the treating
physician.
Eligibility Criteria
Patients were age 60 to 75 years with newly diagnosed therapy-related
AML, AML with antecedent MDS or CMML, or de novo AML with
MDS-related cytogenetic abnormalities (per 2008 WHO criteria).1 Those
who previously received hypomethylating agents, such as azacitidine or
decitabine for MDS or CMML, were eligible. Patients with de novo AML
were required to have MDS-related cytogenetic abnormalities; cytogenetic
screening was available through a central laboratory (University of Rochester,
Rochester, NY), with results available within 48 hours of sample receipt.
Those with acute promyelocytic leukemia, core-binding factor leukemia
known at screening, active CNS leukemia, active second malignancies, or
prior cumulative anthracycline exposure of . 368 mg/m2 daunorubicin or
equivalent were excluded from the study.
End Points and Assessments
The primary end point was OS. Secondary end points were remission
rate (CR, CR + CRi; assessed according to the Revised International
Working Group Criteria for AML22), remission duration, and EFS (time
since random assignment to date of induction failure, relapse from CR +
CRi, or death as a result of any cause). Cumulative incidence of relapse at
6 months and 1 year were calculated among patients who achieved re-
mission; events included relapse from CR + CRi and death, and patients
were censored at the time of HCT (Data Supplement). Safety outcomes
were adverse events, laboratory assessments, and early (30- and 60-day)
mortality.
Statistical Analyses
With accrual within 2 years, minimum follow-up of 1.2 years, and an
estimated median OS of 0.526 years in the 7+3 treatment group,20 a sample
size of 270 patients was expected to result in 236 deaths, giving this trial
93.7% power and a one-sided a of .025 to detect a hazard ratio (HR) of
0.635 between treatment arms. An additional 30 patients were accrued to
account for ineligible patients and patients who withdrew consent.
Efﬁcacy analyses were performed in the intention-to-treat pop-
ulation; safety was evaluated in all treated patients. Time-to-event end
points were evaluated using a stratiﬁed log-rank test to compare treatment
groups. The Kaplan-Meier method was used to estimate the distribution of
these end points over time. HRs and 95% CIs were estimated using a Cox
proportional hazards regression model stratiﬁed by age and AML subtype. A
Mantel-Haenszel test was used to compare remission rates and other
binary end points.
Study Oversight
The trial protocol and modiﬁcations were approved by the in-
dependent ethics committee or institutional review board at each study
site, and the study was conducted according to the principles of the
Declaration of Helsinki and International Conference on Harmonization
Good Clinical Practice guidelines. All patients provided written informed
consent.
An independent data and safety monitoring board oversaw the trial
by assessing safety and efﬁcacy. The study sponsor, Celator Pharmaceu-
ticals, a subsidiary of Jazz Pharmaceuticals, designed the study. Statistical
analyses were performed by Celator/Jazz. All authors had conﬁdential
access to the data, assume responsibility for the accuracy and completeness
of the data, and vouch for the ﬁdelity of the trial to the protocol. The ﬁrst
two and last two authors wrote the ﬁrst manuscript draft with assistance
from professional medical writers funded by Jazz. All authors reviewed the
manuscript through several revisions and made the decision to submit it
for publication.
RESULTS
Patient Population
A total of 309 patients were randomly assigned to CPX-351
(n = 153) or 7+3 (n = 156) and included in the intention-to-treat
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population for efﬁcacy analyses (Fig 1). The safety population
included all patients in the CPX-351 cohort and 151 patients from
the 7+3 cohort (ﬁve patients withdrew consent before the receipt of
treatment). Patient baseline characteristics were balanced between
treatment cohorts (Table 1).
Efficacy
Survival was analyzed after 236 deaths occurred (104 in
CPX-351 cohort, 132 in 7+3 cohort). With a median follow-up of
20.7 months, CPX-351 signiﬁcantly improved OS compared with
7+3 (median, 9.56 v 5.95 months; HR, 0.69; 95% CI, 0.52 to 0.90;
one-sided P = .003; Fig 2A); Kaplan-Meier estimates of 1-year OS
were 41.5% and 27.6% and of 2-year OS were 31.1% and 12.3%.
Prespeciﬁed subgroup analyses by age and AML subtype and post
hoc subgroup analyses indicated signiﬁcantly improved OS with
CPX-351 versus 7+3, irrespective of age (Kaplan-Meier OS shown
in Fig 3A) and in patients with wild-type FMS-like tyrosine kinase
3 (FLT3), therapy-related AML, AML with antecedent MDS
or CMML, and favorable/intermediate cytogenetic risk classiﬁ-
cation (Fig 3B). For additional post hoc analyses see the Data
Supplement. Univariable and multivariable analyses of baseline
factors associated with OS are listed in the Data Supplement.
For the multivariable analysis, signiﬁcant factors were Eastern
Cooperative Oncology Group performance status, karyotype
risk classiﬁcation, platelet count, WBC count, and treatment
group.
CPX-351 was associated with a signiﬁcantly higher overall
remission rate (CR + CRi) versus 7+3 (47.7% v 33.3%; two-sided
P = .016) and CR rate (37.3% v 25.6%; two-sided P = .040;
Table 2). CR + CRi rates among patients with one induction cycle
were 55.2% (58 of 105 patients) for CPX-351 versus 34.0% (34 of
100 patients) for 7+3, and among patients with two induction
cycles, the rates were 31.3% (15 of 48 patients) for CPX-351 versus
35.3% (18 of 51 patients) for 7+3. Higher CR + CRi rates in the
CPX-351 cohort were observed across age groups and AML
subtypes, including patients with MDS-related cytogenetics
(Table 2). Median EFS was signiﬁcantly prolonged with CPX-351
versus 7+3 (2.53 v 1.31 months; HR, 0.74; 95% CI, 0.58 to 0.96;
two-sided P = .021; Fig 2B). Median remission duration was
similar between CPX-351 and 7+3 (6.93 v 6.11 months; two-sided
P = .291).
Assessed for eligibility
(N = 458)
(n = 149)
(n = 82)
(n = 20)
(n = 6)
(n = 5)
(n = 4)
(n = 32)
7+3 arm
Allocated to intervention
   Received allocated intervention
      Induction
 Consolidation
   Did not receive allocated intervention
Patient withdrew consent immediately
   after random assignment
(n = 156)
(n = 151)
(n = 151)
(n = 32)
(n = 5)
(n = 5)
CPX-351 arm
Allocated to intervention
   Received allocated intervention
      Induction
      Consolidation
   Did not receive allocated intervention
(n = 153)
(n = 153)
(n = 153)
(n = 49)
(n = 0)
Analyzed
  Excluded from analysis
(n = 156)
(n = 0)
Analyzed
  Excluded from analysis
(n = 153)
(n = 0)
5-Year
Follow-Up Ongoing
Enrollment
Randomly assigned 
(n = 309)
Allocation
Analysis
Screen failures
   Did not meet disease criteria*
   Prior drug exposure
   Unable to provide informed consent
   Unable to adhere to study protocol
   Did not meet laboratory criteria†
   Other‡
Fig 1. CONSORT diagram. (*) Patients
without conﬁrmation of therapy-related
acute myeloid leukemia (AML), antecedent
myelodysplastic syndrome (MDS) or chronic
myelomonocytic leukemia (CMML), or de
novo AML with MDS-related cytogenetic
abnormalities (n = 43; many of these screen
failures were in patients with de novo AML
without MDS-related cytogenetic abnor-
malities because results of the required
bone marrow biopsy specimens were not
available at the patients’ initial diagnosis);
without pathologic diagnosis of AML
according to WHO criteria with $ 20%
blasts in the peripheral blood or bone
marrow (n = 30); with a history of myelo-
proliferative neoplasms, except CMML
(n = 6); or with acute promyelocytic leu-
kemia (t[15;17]) or favorable cytogenetics (t
[8;21] or inv16 if known at the time of
random assignment; n = 3). (†) Patients
without serum creatinine , 2.0 mg/dL, se-
rum total bilirubin , 2.0 mg/dL, and serum
ALT or AST less than three times the upper
limit of normal. (‡) Other includes patients
with myocardial impairment of any cause
that resulted in heart failure by New York
Heart Association criteria (n = 3); active
(uncontrolled, metastatic) second malig-
nancies (n = 1); active fungal infection,
hepatitis B or C, or HIV (n = 1); cardiac
ejection fraction , 50% (n = 1); incorrect
age (n = 1); secondary malignancy in re-
mission (n = 1); and unspeciﬁed (n = 24).
7+3, standard-of-care cytarabine plus
daunorubicin chemotherapy; CPX-351, dual-
drug liposomal encapsulation of cytarabine
and daunorubicin.
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Ninety-one (29.4%) of 309 patients underwent allogeneic
HCT (52 [34.0%] of 153 in the CPX-351 cohort; 39 [25.0%] of 156
in the 7+3 cohort; two-sided P = .098); characteristics of patients
who underwent HCT are listed in the Data Supplement. The
majority of patients who underwent allogeneic HCTwere in CR or
CRi in both the CPX-351 cohort (30 [57.7%] of 52 and 10 [19.2%]
of 52, respectively) and the 7+3 cohort (19 [48.7%] of 39 and ﬁve
[12.8%] of 39, respectively). An exploratory landmark survival
analysis from the time of HCT favored CPX-351 (HR, 0.46; 95%
CI, 0.24 to 0.89; one-sided P = .009; Fig 2C).
Treatment Exposure
All patients in the safety analysis received the ﬁrst in-
duction; similar proportions in each cohort received a second
induction (CPX-351, 31.4%; 7+3, 33.8%). A higher proportion
of CPX-351 patients achieved CR + CRi and proceeded to re-
ceive the ﬁrst (32.0%) and second (15.0%) postremission
consolidation cycles compared with the 7+3 cohort (21.2% and
7.9%, respectively). The higher proportion of patients who
proceeded to consolidation resulted in a longer median length of
the overall treatment phase with CPX-351 (62 days) versus 7+3
(41 days).
Safety
The types of adverse events, proportions of patients who
experienced them, and severities of events were comparable
between treatment cohorts (Fig 4). The most frequently reported
grade 3 to 5 adverse events in the CPX-351 and 7+3 cohorts were
febrile neutropenia (68.0% v 70.9%), pneumonia (19.6% v
14.6%), and hypoxia (13.1% v 15.2%). Five patients experienced
adverse events that led to treatment discontinuation (CPX-351:
cardiac failure, cardiomyopathy, and acute renal failure [one
patient each]; 7+3: decreased ejection fraction [two patients]).
Although the proportions of patients with adverse events were
comparable between cohorts, the CPX-351 cohort had a longer
median treatment phase and, thus, a longer period of adverse
event reporting; the rate of adverse events (reported during or
within 30 days of the end of treatment) per patient-year was
evaluated to normalize this effect. The median rate of adverse
events per patient-year was 75.68 with CPX-351 versus 87.22
with 7+3.
The median time to neutrophil ($ 500/mL) and platelet
($ 50,000/mL) recovery in patients who achieved CR + CRi after
initial induction chemotherapy was longer with CPX-351 (35.0
and 36.5 days, respectively) versus 7+3 (29 and 29 days; Data
Supplement). Rates of infection-related events of any grade (92.8%
v 92.7%) and grades 3 to 5 (83.7% v 86.1%) were similar with
CPX-351 and 7+3, with low rates of grade 5 infection-related
events in both groups (7.2% v 2.6%). Bleeding events of any grade
were more common with CPX-351 than with 7+3 (74.5% v
59.6%), as were grade 3 to 5 events (11.8% v 8.6%); however, rates
of grade 5 bleeding-related events were equal (2.6% in both
cohorts).
The overall number of deaths was 106 in the CPX-351 arm
(69.3%) and 128 in the 7+3 arm (84.8%); causes of death were
similar between treatment arms (Data Supplement). Early mor-
tality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-
sided P = .149) through day 30 and 13.7% and 21.2% (two-sided
P = .097) through day 60.
DISCUSSION
The survival of patients with sAML has remained disappointingly
short.23 CPX-351 is an example of the CombiPlex platform
(Celator Pharmaceuticals), which, in contrast to traditional
combination chemotherapy regimens, identiﬁes synergistic drug
ratios in vitro and uses an appropriate nanoscale carrier to en-
hance drug delivery. CPX-351 maintains a 5:1 molar ratio of
cytarabine:daunorubicin coencapsulated within a bilamellar li-
posome, enabling intracellular delivery of the synergistic drug
ratio and enhancing uptake in leukemia cells to a greater extent
than normal cells.16-19 In the current study, CPX-351 signiﬁcantly
improved OS, remission rates, and EFS versus conventional 7+3 in
older adults with newly diagnosed high-risk/sAML. CPX-351 efﬁcacy
Table 1. Demographic and Baseline Clinical Characteristics in the
Intention-to-Treat Population
Characteristic CPX-351, No. (%) 7+3, No. (%)
No. of patients 153 156
Age, years
Mean (SD) 67.8 (4.2) 67.7 (4.1)
60-69 96 (62.7) 102 (65.4)
70-75 57 (37.3) 54 (34.6)
Male sex 94 (61.4) 96 (61.5)
Race
White 128 (83.7) 139 (89.1)
Black or African American 7 (4.6) 6 (3.8)
Asian 6 (3.9) 2 (1.3)
Other 12 (7.8) 9 (5.8)
ECOG PS
0 37 (24.2) 45 (28.8)
1 101 (66.0) 89 (57.1)
2 15 (9.8) 22 (14.1)
AML subtype
Therapy-related AML 30 (19.6) 33 (21.2)
AML with antecedent MDS 71 (46.4) 74 (47.4)
With prior HMA 50 (32.7) 55 (35.3)
Without prior HMA 21 (13.7) 19 (12.2)
AML with antecedent CMML 11 (7.2) 12 (7.7)
De novo AML with MDS karyotype 41 (26.8) 37 (23.7)
Prior anthracycline exposure 6 (3.9) 5 (3.2)
All patients with prior HMA exposure* 62 (40.5) 71 (45.5)
No. with cytogenetic risk by NCCN 143 146
Favorable 7 (4.9) 5 (3.4)
Intermediate 64 (44.8) 58 (39.7)
Unfavorable 72 (50.3) 83 (56.8)
Median bone marrow blasts
(aspirate), % (range)
35.0 (5-93) 35.0 (3-97)
No. with WBC count 153 155
, 20 3 109/L 131 (85.6) 131 (84.5)
$ 20 3 109/L 22 (14.4) 24 (15.5)
Abbreviations: 7+3, standard-of-care cytarabine plus daunorubicin chemo-
therapy; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leu-
kemia; CPX-351, dual-drug liposomal encapsulation of cytarabine and
daunorubicin; ECOG PS, Eastern Cooperative Oncology Group performance
status; HMA, hypomethylating agent; MDS, myelodysplastic syndrome; NCCN,
National Comprehensive Cancer Network; SD, standard deviation.
*Includes patients in the prespeciﬁed randomization strata of antecedent MDS
with prior HMA exposure as well as patients in other strata (eg, therapy-related
AML, antecedent CMML) who had previously received HMAs.
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was maintained across AML subtypes and age strata, with improved OS
andhigh rates ofHCT in patients both 60 to 69 and 70 to 75 years of age.
Although the efﬁcacy of CPX-351 ultimately relies on the
activity of cytarabine and daunorubicin, CPX-351 possesses
unique pharmacokinetic and pharmacodynamic properties. CPX-
351 liposomes provide persistent exposure of cytarabine and
daunorubicin in bone marrow, with greater uptake in leukemic
cells than in normal cells at a near-constant 5:1 drug ratio16,19 that
cannot be sustained through administration of free cytarabine and
daunorubicin as a result of their independent and dissimilar
pharmacokinetics.18,24,25 Persistence of CPX-351 liposomes in the
plasma also prolongs drug exposure and preserves the synergistic
5:1 drug ratio, which may increase cytotoxic activity and leukemic
cell killing relative to free drug.24,25 Consistent with this increase
in drug exposure to the bone marrow was the longer time to
recovery of neutrophils and platelets in patients treated with
CPX-351. Although studies have shown increased multidrug
resistance in older patients, particularly those with sAML,5,26
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observations have suggested that CPX-351 may bypass drug efﬂux
pumps by entering leukemia cells as intact liposomes,16
which possibly overcomes drug resistance mechanisms, such as
multidrug resistance phenotype (eg, plasma membrane–localized
P-glycoprotein) and rapid cytarabine deaminase2dependent cytarabine
inactivation.
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Fig 3. Kaplan-Meier estimates of overall survival by (A) age subgroup and (B) baseline patient characteristics. (*) Includes patients in the prespeciﬁed randomization strata
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CPX-351 Versus 7+3 in Older Adults With Newly Diagnosed sAML
Multiple studies have demonstrated low remission rates and
reduced survival in patients with high-risk AML, including sAML
and AML with adverse-risk karyotypes.2,4,13,27,28 However, few
randomized studies have independently reported the effect of novel
therapies in these patients. High-dose cytarabine demonstrated higher
remission and survival rates than standard-dose cytarabine in patients
age# 45 years with newly diagnosed high-risk AML but not in those
age more than 45 years.29 A study of adults age # 60 years dem-
onstrated improved survival with the addition of cladribine but not
ﬂudarabine to 7+3 versus 7+3 alone in a small subgroup of patients
with adverse karyotype.30 The addition of other agents, such as
amonaﬁde, a DNA intercalator that evades drug resistance mecha-
nisms in high-risk AML, did not improve remission rates and survival
when combined with standard-dose cytarabine.28 CPX-351 is the ﬁrst
agent to signiﬁcantly improve survival and remission rates in older
patients with AML with high-risk features.
In both study cohorts, the most frequent grade 3 to 5 adverse
events of febrile neutropenia, pneumonia, and hypoxia occurred at
similar rates. Patients randomly assigned to CPX-351 remained on
study for approximately 50% longer than those in the 7+3 cohort.
Despite differences in the length of treatment phase, the proportion of
patients who experienced adverse events in the CPX-351 cohort was
comparable with that of those in the 7+3 cohort, which culminated in
a lower rate of adverse events per patient-year and suggests that CPX-
351 may have a more favorable overall toxicity proﬁle than 7+3. The
rates of early (30- and 60-day) mortality seemed lower with CPX-351
despite an increase in the time to neutrophil and platelet recovery
in CPX-351–treated patients. In addition, the improved post-HCT
survival observed in patients randomly assigned to CPX-351 suggests
that the response is deeper than that achieved with 7+3.31 Additional
studies are warranted to conﬁrm these ﬁndings.
Collectively, these clinical data support the adoption of CPX-351
for the initial treatment of adults with high-risk/sAML as well as the
investigation of CPX-351 in other cohorts. For example, in preclinical
studies, leukemia blasts from patients with FLT3-ITD were ﬁve-fold
more sensitive to CPX-351 thanwild-type blasts,32 and, in the current
study, a trend toward improved survival was observed with CPX-351
versus 7+3 in the small subgroup of patients with baseline FLT3
mutations. These preliminary ﬁndings support additional study in
Table 2. Best Response Rates
Response
CPX-351,
No. (%)
7+3,
No. (%) OR (95% CI)
No. of patients 153 156
CR + CRi 73 (47.7) 52 (33.3) 1.77 (1.11 to 2.81)*
CR 57 (37.3) 40 (25.6) 1.69 (1.03 to 2.78)†
Age group
No. in 60-69–year age-group 96 102
CR + CRi 48 (50.0) 37 (36.3) 1.76 (1.00 to 3.10)
CR 38 (39.6) 27 (26.5) 1.82 (1.00 to 3.32)
No. in 70-75–year age-group 57 54
CR + CRi 25 (43.9) 15 (27.8) 2.03 (0.92 to 4.49)
CR 19 (33.3) 13 (24.1) 1.58 (0.69 to 3.62)
AML subtype
No. with therapy-related AML 30 33
CR + CRi 14 (46.7) 12 (36.4) 1.53 (0.56 to 4.20)
CR 11 (36.7) 10 (30.3) 1.33 (0.47 to 3.81)
No. with AML with
antecedent MDS with
prior HMA exposure
50 55
CR + CRi 18 (36.0) 18 (32.7) 1.16 (0.52 to 2.59)
CR 13 (26.0) 10 (18.2) 1.58 (0.62 to 4.02)
No. with AML with
antecedent MDS
without prior HMA
exposure
21 19
CR + CRi 14 (66.7) 7 (36.8) 3.43 (0.93 to 12.59)
CR 12 (57.1) 7 (36.8) 2.29 (0.64 to 8.15)
No. with AML with
antecedent CMML
11 12
CR + CRi 4 (36.4) 3 (25.0) 1.71 (0.29 to 10.30)
CR 2 (18.2) 3 (25.0) 0.67 (0.09 to 4.99)
No. with de novo AML with
MDS karyotype
41 37
CR + CRi 23 (56.1) 12 (32.4) 2.66 (1.06 to 6.71)
CR 19 (46.3) 10 (27.0) 2.33 (0.90 to 6.03)
Cytogenetic risk at screening
No. with favorable/
intermediate
71 63
CR + CRi 39 (54.9) 30 (47.6) 1.26 (0.62 to 2.54)
CR 30 (42.3) 21 (33.3) 1.46 (0.68 to 3.13)
No. with unfavorable 72 83
CR + CRi 31 (43.1) 18 (21.7) 2.79 (1.34 to 5.82)
CR 25 (34.7) 15 (18.1) 2.43 (1.12 to 5.28)
Baseline FLT3 mutation status
No. with FLT3 mutation 22 21
CR + CRi 15 (68.2) 5 (23.8) 6.86 (1.78 to 26.36)
CR 12 (54.5) 4 (19.0) 5.10 (1.29 to 20.17)
Overall HMA experience
No. patients with prior HMA
exposure‡
62 71
CR + CRi 23 (37.1) 20 (28.2) 1.50 (0.73 to 3.12)
CR 16 (25.8) 11 (15.5) 1.90 (0.80 to 4.48)
NOTE. ORs are calculated with the 7+3 cohort as the reference group.
Abbreviations: 7+3, standard-of-care cytarabine plus daunorubicin chemo-
therapy; AML, acute myeloid leukemia; CMML, chronic myelomonocytic
leukemia; CPX-351, dual-drug liposomal encapsulation of cytarabine and
daunorubicin; CR, complete remission; CRi, CR with incomplete neutrophil or
platelet count recovery; FLT3, FMS-like tyrosine kinase 3; HMA, hypo-
methylating agent; MDS, myelodysplastic syndrome; OR, odds ratio.
*Two-sided P = .016.
†Two-sided P = .040.
‡Includes patients in the prespeciﬁed randomization strata of antecedent MDS
with prior HMA exposure as well as patients in other strata (eg, therapy-related
AML, antecedent CMML) who had previously received HMAs.
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Fig 4. Most frequently reported adverse events. The percentage of patients with
grade 1 and 2 and grade 3 to 5 events are shown for all adverse events that
occurred in. 5% of patients in either treatment group as grade 3 to 5 events. 7+3,
standard-of-care cytarabine plus daunorubicin chemotherapy; CPX-351, dual-drug
liposomal encapsulation of cytarabine and daunorubicin.
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patients with FLT3 mutations. In addition, many genetic mutations
found in sAML are shared with MDS,33 and data have indicated that
many cases of de novo AML share a similar mutation proﬁle to
clinically deﬁned sAML, with similarly poor outcomes.34 Together,
these observations suggest that CPX-351 may ultimately prove ef-
fective in high-risk patients with MDS and other high-risk de novo
AML, particularly those in whom allogeneic HCT is contemplated.
The combination of CPX-351 with small-molecule inhibitors (eg,
enasidenib, midostaurin, venetoclax) and/or conjugated monoclonal
antibodies also may improve efﬁcacy in speciﬁc subsets of patients.
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